Low Temperature Plasma Ablation Combined Lacrimal Duct Catheterization in the Treatment of Lacrimal Duct Obstructive
Study Details
Study Description
Brief Summary
To compare the clinical effects of low temperature plasma ablation combined with lacrimal duct catheterization and YAG lacrimal duct laser combined with lacrimal duct catheterization in the treatment of lacrimal duct obstruction
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Low-temperature plasma technology has developed rapidly in recent decades and is now widely used in ophthalmology, otolaryngology, orthopedics, urology and other fields .The low-temperature plasma surgery system relies on a 100kHz radio frequency electric field to excite normal saline (0.9% NaCl) to generate plasma energy, and relies on a 50-100 μm plasma layer generated at the front of the plasma knife to perform precise cutting, ablation and hemostaxy. But the application of this technique in the field of lacrimal duct still needs the accumulation of clinical experience.This study was aimed to compare the clinical effects of low temperature plasma ablation combined with lacrimal duct catheterization and YAG lacrimal duct laser combined with lacrimal duct catheterization in the treatment of lacrimal duct obstruction
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Low temperature plasma ablation with lacrimal duct catheterization The experimental group received low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization |
Procedure: Low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization
The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
|
| Placebo Comparator: YAG lacrimal duct laser combined with lacrimal duct catheter Control group received YAG lacrimal duct laser combined with lacrimal duct catheterization |
Procedure: YAG lacrimal duct laser combined with lacrimal duct catheter
The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
|
Outcome Measures
Primary Outcome Measures
- Change between 1 week, 1, 2, 3 months and 6 months postoperatively of degree of watering [Postoperatively 1 week, 1, 2, 3 months, 6 months]
The degree of watering was evaluated and classified according to the following clinical symptoms: 1 = no epiphora, 2 = minimal epiphora outdoors but only with wind or cold, 3 = troublesome epiphora outdoors but not indoors, 4 = epiphora indoors and outdoors
Secondary Outcome Measures
- Change between 1 week, 1, 2, 3 months and 6 months postoperatively of intraoperative complications [Postoperatively 1 week, 1, 2, 3 months, 6 months]
The complications of laser or plasma treatment involve abnormal tear secretion, acute and chronic purulent dacryocystitis, sepsis, false passage formation, epistaxis, and subcutaneous emphysema
- Change between 1 week, 1, 2, 3 months and 6 months postoperatively of pain score [Postoperatively 1 week, 1, 2, 3 months, 6 months]
The VAS pain grade was recorded on a 0-10 scale, with 0 being no pain and 10 being the most intense pain
Eligibility Criteria
Criteria
Inclusion Criteria:
-
① sign the informed consent for this study Voluntarily
-
≥18 years old and < 70 years old (3) Single lacrimal tract obstruction was included in the study
-
no purulent secretion of lacrimal passage
Exclusion Criteria:
-
Patients who meet any of the following criteria will not be eligible for inclusion in this study:
-
Have a history of lacrimal duct surgery, including lacrimal duct catheterization, laser lacrimal duct plasty, etc
-
Have a history of allergy to hormones and antibiotics
-
congenital lacrimal duct malformation
-
nasal trauma and deformation ⑤ Patients with severe abnormal liver and kidney function and cardiovascular and cerebrovascular diseases In addition to lacrimal duct obstruction, there are other ophthalmic diseases ⑦ Exclude diabetes
-
Exclusion of pregnancy, lactation women ⑨ Not willing to participate in research
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Second Affiliated Hospital of Zhejiang University Hospital | Hangzhou | China |
Sponsors and Collaborators
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Zhejiang Provincial People's Hospital
- The First Affiliated Hospital with Nanjing Medical University
Investigators
- Study Chair: lin lin, Second Affiliated Hospital of Zhejiang University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2018-151